Evaluation of an automated nucleic acid extractor for hepatitis C virus load quantification

Journal of Clinical Microbiology

Volumn 47, Issue 3, 2009, Pages 811-813

  Martró, Elisa ^a,b,c   García Sierra, Nerea ^a,b   González, Victoria ^a,b,c   Saludes, Verónica ^a,b,c   Matas, Lurdes ^a,b,c   Ausina, Vicenç ^a,b,d  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEIC ACID;

ARTICLE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; VIRUS DETECTION; VIRUS LOAD;

AUTOMATION; HEPACIVIRUS; HEPATITIS C; HUMANS; REPRODUCIBILITY OF RESULTS; RNA, VIRAL; SERUM; VIRAL LOAD;

HEPATITIS C VIRUS;

EID: 62749189179     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.02181-08     Document Type: Article

References (12)

1. Boom, R., C. J. A. Sol, M. M. M. Salimans, C. L. Jansen, P. M. E. Wertheimvan Dillen, and J. van der Noordaa. 1990. Rapid and simple method for purification of nucleic acids. J. Clin. Microbiol. 28:495-503.
2. Halfon, P., M. Bourlière, G. Pénaranda, H. Khiri, and D. Ouzan. 2006. Real-time PCR assays for hepatitis C virus (HCV) RNA quantitation are adequate for clinical management of patients with chronic HCV infection. J. Clin. Microbiol. 44:2507-2511.
3. Lee, S. S., E. J. Heathcote, K. R. Reddy, S. Zeuzem, M. W. Fried, T. L. Wright, P. J. Pockros, D. Haussinger, C. I. Smith, A. Lin, and S. C. Pappas. 2002. Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). J. Hepatol. 37:500-506.
4. Loens, K., K. Bergs, D. Ursi, H. Goossens, and M. Ieven. 2007. Evaluation of NucliSens easyMAG for automated nucleic acid extraction from various clinical specimens. J. Clin. Microbiol. 45:421-425.
5. National Institutes of Health. 2006. National Institutes of Health Consensus Development Conference statement. Management of hepatitis C: 2002-2004. National Institutes of Health, Bethesda, MD. http://consensus.nih. gov.
6. Sanchez-Tapias, J. M., M. Diago, P. Escartin, J. Enriquez, M. Romero-Gomez, R. Barcena, J. Crespo, R. Andrade, E. Martinez-Bauer, R. Perez, M. Testillano, R. Planas, R. Sola, M. Garcia-Bengoechea, J. Garcia-Samaniego, M. Munoz-Sanchez, and R. Moreno-Otero. 2006. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 131:451-460.
7. Schneider, G., K. Kuper, K. Abravaya, C. Mullen, M. Schmidt, and M. Sprenger-Haussels. 2007. Performance evaluation of the QIAGEN EZ1 DSP virus kit with Abbott RealTime HIV-1, HCV and HBV assays. Abstr. 17th Eur. Congr. Clin. Microbiol. Infect. Dis. European Society of Clinical Microbiology and Infectious Diseases, Paris, France.
8. Schutten, M., E. Fries, C. Burghoorn-Maas, and H. G. Niesters. 2007. Evaluation of the analytical performance of the new Abbott RealTime RT-PCRs for the quantitative detection of HCV and HIV-1 RNA. J. Clin. Virol. 40:99-104.
9. Shiffman, M. L., F. Suter, B. R. Bacon, D. Nelson, H. Harley, R. Sola, S. D. Shafran, K. Barange, A. Lin, A. Soman, and S. Zeuzem. 2007. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N. Engl. J. Med. 357:124-134.
10. Tiemann, C., D. Knoop, C. Dunn, C. Huber, and S. Schaffer. 2007. Performance evaluation of a new instrument for genomic viral DNA or RNA extraction with HIV-1 and HCV viral load assays, abstr. PCR007. Abstr. 10th Annu. Eur. Soc. Clin. Virol. Meet. European Society for Clinical Virology, Leuven, Belgium.
11. World Health Organization. 2005. State of the art vaccine research development, p.81-88. World Health Organization, Geneva, Switzerland. http://www.who.int/vaccine-research/documents/stateoftheart/en/index.html.
12. Zeuzem, S., M. Buti, P. Ferenci, J. Sperl, Y. Horsmans, J. Cianciara, E. Ibranyi, O. Weiland, S. Noviello, C. Brass, and J. Albrecht. 2006. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J. Hepatol. 44:97-103.